#NAFLD

NAFLD is associated with risk factors such as obesity and inflammatory biomarkers and with events including heart attacks and strokes.

For people with NAFLD or NASH, treating metabolic problems may offer benefits beyond liver disease.

Advanced fatty liver disease led to a greater need for medical care and more difficulty with daily activities.

In 2022, fatty liver disease accounted for nearly a quarter of all liver cancer cases on the transplant waiting list.

Men, people with obesity and people who smoke are more likely to develop NAFLD.

Lean people had a higher mortality rate despite experiencing fewer metabolic problems.

Restoration of gut function and microbial diversity could lead to improvement of hepatic encephalopathy.

While hepatitis C remains a leading cause, cirrhosis is increasingly caused by fatty liver disease and alcohol use.

People who used cholesterol-lowering medications had a 40% lower risk for liver disease progression.

Changes in liver fat, metabolic factors and liver enzymes were comparable with both dietary interventions.

A second meta-analysis found that people with cirrhosis had higher COVID mortality.

People who exercised saw a beneficial decrease in liver fat even if they did not lose weight.

The burden of viral and nonviral liver disease remains high even in the setting of hepatitis C microelimination.

People with NAFLD who fasted on alternate days also experienced drops in weight and waist size.

People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.

Early detection and adopting healthier lifestyles are critical to minimize long-term liver damage.